NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit. Additional information about each case can be found at the link provided.
Rockwell Medical (NASDAQ: RMTI)
On July 27, 2018, a complaint was filed alleging that between November 8, 2017 and June 26, 2018, defendants made false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that the Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for Triferic; (2) the estimated reserves in Rockwell’s Form 10-Q for the quarter ended March 31, 2018 are misstated; (3) there was a material weakness in Rockwell’s internal control over financial reporting; (4) consequently, Rockwell’s internal control over financial reporting was ineffective during the Class Period; (5) Robert L. Chioini, former Chief Executive Officer of Rockwell, withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of Rockwell’s Board; and (6) as a result, defendants’ statements about Rockwell’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
If you are a long term stockholder of Rockwell continuously holding shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
For more information on this investigation visit http://bespc.com/rmti
Amneal Pharmaceuticals, Inc. (NYSE: AMRX)
For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products. Recently, the Company was among those sued in a wide-ranging lawsuit brought by 44 state attorneys general alleging an illegal conspiracy to inflate prices of more than 100 generic drugs, sometimes by more than 1,000%, and stifle competition.
If you are a long term stockholder of Amneal Pharmaceuticals continuously holding shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
For more information on this investigation visit http://bespc.com/amrx
Kraft Heinz Company (NASDAQ: KHC)
On February 21, 2019, Kraft announced it had improperly accounted for the costs of products sold and that it recorded impairment charges of $15.4 billion to lower the carrying amount of goodwill in certain reporting units. Kraft also announced receipt of an SEC subpoena regarding an investigation into Kraft's accounting policies, procedures, and internal controls and that Kraft had been operating with material weaknesses in its system of internal controls over financial reporting. On this news, Kraft stock declined approximately 27.5%, from $48.18/share to $34.95/share.
If you are a long term stockholder of Kraft Heinz Company continuously holding shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
For more information on this investigation visit http://bespc.com/khc
Intuit, Inc. (NASDAQ: INTU)
For several years, Intuit operated under an agreement with the Internal Revenue Service to provide a free version of its commercial tax filing products called TurboTax “Freedom Edition” to low-income taxpayers in exchange for the IRS agreeing not to compete by offering its own free online tax filing service. However, the Company has recently been sued in a consumer class action lawsuit alleging that it defrauded taxpayers through a scheme to deliberately hide or otherwise limit access to its free service, while aggressively marketing another program as free even though it had limited functionality and deceived users otherwise eligible for free filing into paying for product upgrades to file their taxes.
Our investigation is focusing on whether Intuit’s officers and/or directors breached their fiduciary duties to Intuit’s shareholders or otherwise violated state or federal laws.
If you are a long term stockholder of Intuit continuously holding shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
For more information on this investigation visit http://bespc.com/intu